Yinhua CSI Innovative Drugs Industry ETF(159992) falls 1.96%, with a net inflow of 502 million yuan over the past 16 trading days

NewTimeSpace (newtimespace.com) News, as of 14:06 on May 28, 2026, Yinhua Innovative Drug ETF (159992) fell 1.96%, with the latest price at 0.75 yuan. (The stocks listed above are only index constituents and do not constitute any specific recommendation.)

In terms of liquidity, Yinhua Innovative Drug ETF recorded an intraday turnover rate of 3.42% and a trading volume of 486 million yuan. Over a longer time frame, as of May 27, the ETF's average daily trading volume over the past month reached 701 million yuan, ranking first among comparable funds.

In terms of scale, Yinhua Innovative Drug ETF saw a significant increase of 1.232 billion yuan in scale over the past six months, with the new scale increase ranking 2/7 among comparable funds. (Data source: Wind)

In terms of shares, Yinhua Innovative Drug ETF experienced a significant increase of 575 million units in share count month-to-date, with the new share increase ranking 2/7 among comparable funds. (Data source: Wind)

In terms of capital flows, the latest net outflow from Yinhua Innovative Drug ETF was 185 million yuan. Over a longer time frame, within the past 16 trading days, it attracted a total of 502 million yuan in net inflow. (Data source: Wind)

Data shows that leveraged funds are continuously positioning. Yinhua Innovative Drug ETF recorded a net margin financing purchase of 4.8319 million yuan month-to-date, with the latest margin financing balance standing at 664 million yuan. (Data source: Wind)

As of May 27, the net value of Yinhua Innovative Drug ETF rose by 14.28% over the past two years. From the perspective of return capability, as of May 27, 2026, since its inception, the ETF achieved a highest single-month return of 22.79%, a longest streak of consecutive up months of 4 months, a maximum cumulative gain during that streak of 53.27%, and an average return of 6.47% in up months. As of May 27, 2026, the ETF's annualized excess return over its benchmark for the past two years was 0.62%.

In terms of drawdown, as of May 27, 2026, Yinhua Innovative Drug ETF recorded a drawdown of 0.18% relative to its benchmark since the beginning of the year.

In terms of fees, Yinhua Innovative Drug ETF has a management fee rate of 0.50% and a custodian fee rate of 0.05%.

In terms of tracking accuracy, as of May 27, 2026, the tracking error of Yinhua Innovative Drug ETF since the beginning of the year was 0.019%, achieving relatively high tracking accuracy among comparable funds.

From a valuation perspective, the latest price-to-earnings (PE-TTM) ratio of the CSI Innovative Drug Industry Index, which Yinhua Innovative Drug ETF tracks, is only 44.34 times, standing at the 10.65% percentile over the past year. This means the valuation is lower than over 89.35% of the time in the past year, placing it at a historical low.

Yinhua Innovative Drug ETF closely tracks the CSI Innovative Drug Industry Index. The CSI Innovative Drug Industry Index selects no more than 50 of the most representative listed company securities whose main businesses involve innovative drug research and development as index constituents, in order to reflect the overall performance of the securities of listed companies in the innovative drug industry.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.